RESUMO
Objective. Primary hepatic lymphoma is a rare disease. And the clinical manifestations of this disease are nonspecific. The objective of this paper is to improve clinicians' understanding of this disease. Methods. We analyzed the clinical characteristics of a case of primary hepatic lymphoma in association with hepatitis B virus infection and reviewed the literature. Conclusion. The clinical manifestations of primary hepatic lymphoma are nonspecific. And it is easily misdiagnosed. Postoperative radiotherapy of patients with early stage was previously speculated to achieve favorable improvement. The application of targeted therapeutic drugs, chemotherapy, or combined local radiotherapy has become the first-line treatment strategy.
RESUMO
OBJECTIVE: The aim of this study was to investigate the clinical value of urine Prostate cancer antigen 3 (PCA3) test in the diagnosis of prostate cancer by pooling the published data. METHODS: The clinical trials about urine PCA3 test in the diagnosis of prostate cancer were searched in the PubMed (January, 1966-July, 2014). Cochrane library (Section 3, 2013), CNKI (March, 1994-July, 2014). All relevant prospective studies of urine PCA3 test in the diagnosis of prostate cancer were screened. The aggregated sensitivity, specificity, positive likely hood ratio (+LR), negative likely hood ratio (-LR), diagnosis odds ratio (DOR) and area under the area under curve (AUC) were calculated by using Meta-disc 1.4 and STATA 11.0 statistic software. RESULTS: Finally, a total of 13 trials including 3245 subjects were included in this meta-analysis. The pooled sensitivity, specificity, +LR, -LR, DOR and AUC were 0.62 (95% confidence interval [CI]: 0.59-0.65), 0.75 (95% CI: 0.73-0.76), 6.16 (95% CI: 3.39-11.21), 0.50 (95% CI: 0.43-0.59), 5.49 (95% CI: 3.76-8.019) and 0.75 (95% CI: 0.71-0.78), respectively. CONCLUSION: Urine PCA3 test has acceptable sensitivity and specificity in the diagnosis of prostate cancer, which can be used as non-invasive method for diagnosis of prostate cancer.